Abstract CT127: Phase I and expanded access experience of LOXO-195 (BAY 2731954), a selective next-generation TRK inhibitor (TRKi)
Sign Up to like & getrecommendations! Published in 2019 at "Clinical Trials"
DOI: 10.1158/1538-7445.am2019-ct127
Abstract: Background: Larotrectinib, a selective TRKi, is now FDA approved for pediatric and adult TRK-fusion solid tumors, regardless of tumor origin. Emergent TRK kinase mutations are a common mechanism of resistance to TRKis. LOXO-195, a selective… read more here.
Keywords: trk kinase; trk; expanded access; loxo 195 ... See more keywords